Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial)

Trial Profile

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms Remain
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Preliminary results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 17 Jun 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top